Skip to content
Screener

Stock-Based Comp at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$83M+10.7%
Labcorp Holdings logo
Labcorp HoldingsLH
$34.9M+2.3%
IQVIA logo
IQVIAIQV
$95M+58.3%
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
$12.6M-44.5%
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
$6.9M+5.2%
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
$3.78M

Other financials

Income statement

See full
Revenue$707.3M+17.2%
Operating income$146.8M+16.2%
Net income$121.4M+34.5%
EPS (diluted)$4.25+37.1%

Balance sheet

See full
Cash & equivalents$502.7M+985%
Total debt$144.1M-3.8%
Total equity$433.9M+152%
Total assets$2.1B+30.9%

Cash flow

See full
Operating cash flow$162.0M+9.1%
CapEx$23.9M+291%
Free cash flow$138.1M-3.0%

Valuation

See full
Market cap$16.41B+35.7%
Enterprise value$16.05B+31.6%
P/E33.4×+4.5×
P/S5.9×+0.5×

Profitability

See full
Operating margin21%-0.4pp
Net margin17.7%-1.1pp
FCF margin25.4%-0.6pp

Returns & leverage

See full
Return on equity162.2%+72.8pp
Debt / equity0.3×-0.5×
Current ratio0.7×+0.3×

Where this comes from

Reported directly by Medpace Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The source filing: Medpace Holdings, Inc.’s 10-Q, filed July 23, 2026.

Filed
Jul 23, 2026, 4:03 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001668397-26-000025
(Amounts in thousands)Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation13,30613,471
Amortization310473
Stock-based compensation expense9,26622,843
Noncash lease expense11,90211,687
Deferred income tax provision22,82434,856
Other255(520)
Changes in assets and liabilities:

Item 1. Financial Statements (unaudited)

FAQ

What is Medpace Holdings, Inc.'s stock-based comp?
Medpace Holdings, Inc. (MEDP) reported stock-based comp of $2.81M in Q2 2026.
How has Medpace Holdings, Inc.'s stock-based comp changed year-over-year?
Medpace Holdings, Inc.'s stock-based comp decreased by 17.7% year-over-year, from $3.42M to $2.81M.
What is the long-term trend for Medpace Holdings, Inc.'s stock-based comp?
Over 4 years (2021 to 2025), Medpace Holdings, Inc.'s stock-based comp has grown at a 22.2% compound annual growth rate (CAGR), from $14.47M to $32.26M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Ask your AI about Medpace Holdings, Inc.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude